Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
International Endodontic Journal
|
September 29, 2020
Biofilm removal from a simulated isthmus and lateral canal during syringe irrigation at various flow rates: a combined experimental and Computational Fluid Dynamics approach
T C Pereira, C Boutsioukis, R J B Dijkstra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Cancer Immunology, Immunotherapy : CII
|
August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
C Schmitt, E P Hoefsmit, T Fangmeier, et al.
Mbio
|
January 20, 2021
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses <i>In Vitro</i>
Nathan E Stone, Sierra A Jaramillo, Ashley N Jones, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Journal for Immunotherapy of Cancer
|
April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Patricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Journal for Immunotherapy of Cancer
|
July 21, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Elisa A Rozeman, Judith M Versluis, Karolina Sikorska, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
International Endodontic Journal
|
September 29, 2020
Biofilm removal from a simulated isthmus and lateral canal during syringe irrigation at various flow rates: a combined experimental and Computational Fluid Dynamics approach
T C Pereira, C Boutsioukis, R J B Dijkstra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Cancer Immunology, Immunotherapy : CII
|
August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
C Schmitt, E P Hoefsmit, T Fangmeier, et al.
Mbio
|
January 20, 2021
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses <i>In Vitro</i>
Nathan E Stone, Sierra A Jaramillo, Ashley N Jones, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Journal for Immunotherapy of Cancer
|
April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Patricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Journal for Immunotherapy of Cancer
|
July 21, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Elisa A Rozeman, Judith M Versluis, Karolina Sikorska, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 8